Wanqin Liao

Wanqin Liao

Auto-generated profile, based on publicly available information

Wanqin Liao

School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 December 2020 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
WLWanqin Liao
Wanqin Liao
LFLixia Fan
Lixia Fan
MLMingchan Li
Mingchan Li
HDHuizhi Deng
Huizhi Deng
AYAnping Yang
Anping Yang
FLFang Liu
Fang Liu

1 September 2007 in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
XLXu-Fang Liang
Xu-Fang Liang
GLGuang-Zhao Li
Guang-Zhao Li
WYWei Yao
Wei Yao
LCLai-Wan Cheong
Lai-Wan Cheong
WLWan-Qin Liao
Wan-Qin Liao

24 June 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RPRulu Pan
Rulu Pan
JDJuji Dai
Juji Dai
WLWeicheng Liang
Weicheng Liang
HWHongxiao Wang
Hongxiao Wang
LYLin Ye
Lin Ye
XLXincheng Lu
Xincheng Lu
Phosphodiesterase 4D interacting protein (PDE4DIP) is a centrosome/Golgi protein associated with cyclic nucleotide phosphodiesterases. PDE4DIP is commonly mutated in human cancers, and its alteration in mice leads to a predisposition to intestinal cancer. However, the biological function of PDE4DIP in human cancer remains obscure. Here, we report for the first time the oncogenic role of PDE4DIP in colorectal cancer (CRC) growth and adaptive MEK inhibitor (MEKi) resistance. We show that the expression of PDE4DIP is upregulated in CRC tissues and associated with the clinical characteristics and poor prognosis of CRC patients. Knockdown of PDE4DIP impairs the growth of KRAS-mutant CRC cells by inhibiting the core RAS signaling pathway. PDE4DIP plays an essential role in the full activation of oncogenic RAS/ERK signaling by suppressing the expression of the RAS GTPase-activating protein (RasGAP) neurofibromin (NF1). Mechanistically, PDE4DIP promotes the recruitment of PLCγ/PKCε to the Golgi apparatus, leading to constitutive activation of PKCε, which triggers the degradation of NF1. Upregulation of PDE4DIP results in adaptive MEKi resistance in KRAS-mutant CRC by reactivating the RAS/ERK pathway. Our work reveals a novel functional link between PDE4DIP and NF1/RAS signal transduction and suggests that targeting PDE4DIP is a promising therapeutic strategy for KRAS-mutant CRC.

22 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
RPRulu Pan
Rulu Pan
JDJuji Dai
Juji Dai
WLWeicheng Liang
Weicheng Liang
HWHongxiao Wang
Hongxiao Wang
LYLin Ye
Lin Ye
XLXincheng Lu
Xincheng Lu
Phosphodiesterase 4D interacting protein (PDE4DIP) is a centrosome/Golgi protein associated with cyclic nucleotide phosphodiesterases. PDE4DIP is commonly mutated in human cancers, and its alteration in mice leads to a predisposition to intestinal cancer. However, the biological function of PDE4DIP in human cancer remains obscure. Here, we report for the first time the oncogenic role of PDE4DIP in colorectal cancer (CRC) growth and adaptive MEK inhibitor (MEKi) resistance. We show that the expression of PDE4DIP is upregulated in CRC tissues and associated with the clinical characteristics and poor prognosis of CRC patients. Knockdown of PDE4DIP impairs the growth of KRAS-mutant CRC cells by inhibiting the core RAS signaling pathway. PDE4DIP plays an essential role in the full activation of oncogenic RAS/ERK signaling by suppressing the expression of the RAS GTPase-activating protein (RasGAP) neurofibromin (NF1). Mechanistically, PDE4DIP promotes the recruitment of PLCγ/PKCε to the Golgi apparatus, leading to constitutive activation of PKCε, which triggers the degradation of NF1. Upregulation of PDE4DIP results in adaptive MEKi resistance in KRAS-mutant CRC by reactivating the RAS/ERK pathway. Our work reveals a novel functional link between PDE4DIP and NF1/RAS signal transduction and suggests that targeting PDE4DIP is a promising therapeutic strategy for KRAS-mutant CRC.